AC Immune (ACIU)
Develops protein-misfolding therapies and diagnostics for neurodegenerative diseases.
Something off on this page? Send us feedback.
Uses its SupraAntigen and Morphomer platforms to develop therapeutics and diagnostics for neurodegenerative diseases tied to misfolded proteins. Proprietary clinical development is paired with pharmaceutical partnerships that provide non-dilutive funding.
Built around the SupraAntigen and Morphomer technology platforms, the Lausanne-based clinical-stage company develops therapeutic and diagnostic programs for neurodegenerative diseases associated with misfolded proteins. Its work includes active immunotherapies and selected small-molecule programs, targeting conditions including Alzheimer’s and Parkinson’s disease.
Proprietary development is paired with strategic pharmaceutical collaborations, including relationships with Takeda, Janssen, and Lilly. Those collaborations can advance parts of the pipeline and supply non-dilutive funding for proprietary programs.
Following a strategic review, the company narrowed its pipeline to selected clinical programs and operational priorities. It operates as a Swiss company from Lausanne while its common shares trade on Nasdaq under ACIU.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Mar 13, 2026 | Jefferies | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $91.8M · Total debt $5.0M · Total assets $183.3M · Shareholders' equity $42.9M
- Revenue
- $18.4M
- Operating income
- $1.5M
- Net income
- $2.3M
Reported in CHF, converted at the latest exchange rate
No dividends on record.
| Institutions | 24.05% | 24.47M ADS | |
|---|---|---|---|
| 47 holders · as of Jun 30, 2026 | |||
| Insiders | 4.41% | 4.49M ADS | |
| 8 holders · as of Jun 15, 2026 | |||
| Other | 71.54% | 72.79M ADS | |
| remainder | |||
101.74M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BVF Inc/ILInstitution | 19.48% | 19.82M ADS | as of Jun 30, 2026 |
Andrea PfeiferInsiderdirector, officer: Chief Executive Officer | 3.77% | 3.83M ordinary | filed May 18, 2026 |
Wells Fargo & Company/MNInstitution | 0.99% | 1.00M ADS | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 0.83% | 840,127 ADS | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 0.76% | 773,594 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 15, 2026 | Andrea Pfeifer | director, officer: Chief Executive Officer | −10,000 | $2.79 |
| Apr 15, 2026 | Andrea Pfeifer | director, officer: Chief Executive Officer | +10,000 | $3.14 |
| Apr 15, 2026 | Andrea Pfeifer | director, officer: Chief Executive Officer | −10,000 | $3.14 |
- Eli Lilly
Tau PET and neuroinflammation programs in Alzheimer's and Parkinson's
- Lantheus
Registrational tau PET imaging program for Alzheimer's disease
- Teva (ADR)
Phase 2 alpha-synuclein therapy for multiple system atrophy
- Acumen Pharmaceuticals
Phase 2 amyloid-beta oligomer antibody for early Alzheimer's
- Prothena
Amyloid-, tau-, and alpha-synuclein programs in neurodegeneration
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AC Immune | $2.74 | +3.15% | $270.2M | — | — | 12.6 | +823.6% |
| Eli Lilly | $1,171.24 | +0.55% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Lantheus | $100.20 | −0.08% | $6.53B | 24.2 | 17.8 | 4.2 | +2.7% |
| Teva (ADR) | $39.65 | −1.02% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Acumen Pharmaceuticals | $2.67 | +2.90% | $187.1M | — | — | — | — |
| Prothena | $9.06 | +6.46% | $445.5M | — | — | 8.2 | −77.2% |
| Median | 39.1 | 17.8 | 6.2 | +0.9% |